02207nas a2200325   4500000000100000008004100001260004400042653002300086653002800109653002700137653002300164653000500187100001600192700002000208700001600228700002200244700001300266700001500279700001200294700001100306700001700317700001900334700001200353245010700365856008300472300000900555490000600564520129700570022001401867       2016                            d  bSpringer Science and Business Media LLC10alateral flow assay10aLeprosy, Multibacillary10aPaucibacillary leprosy10aBiomarker profiles10a1 avan Hooij A1 aTjon Kon Fat EM1 aRichardus R1 avan den Eeden SJF1 aWilson L1 ade Dood CJ1 aFaber R1 aAlam K1 aRichardus JH1 aCorstjens PLAM1 aGeluk A00aQuantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy  uhttps://scholarlypublications.universiteitleiden.nl/access/item%3A4256765/view  a1-110 v63 a<p>Leprosy is a debilitating, infectious disease caused by Mycobacterium leprae. Despite the availability of multidrug therapy, transmission is unremitting. Thus, early identification of M. leprae infection is essential to reduce transmission. The immune response to M. leprae is determined by host genetics, resulting in paucibacillary (PB) and multibacillary (MB) leprosy associated with dominant cellular or humoral immunity, respectively. This spectral pathology of leprosy compels detection of immunity to M. leprae to be based on multiple, diverse biomarkers. In this study we have applied quantitative user friendly lateral flow assays (LFAs) for four immune markers (anti-PGL-I antibodies, IL-10, CCL4 and IP-10) for whole blood samples from a longitudinal BCG vaccination field-trial in Bangladesh. Different biomarker profiles, in contrast to single markers, distinguished M. leprae infected from non-infected test groups, patients from household contacts (HHC) and endemic controls (EC), or MB from PB patients. The test protocol presented in this study merging detection of innate, adaptive cellular as well as humoral immunity, thus provides a convenient tool to measure specific biomarker profiles for M. leprae infection and leprosy utilizing a field-friendly technology.</p>
  a2045-2322